US HB4087 | 2011-2012 | 112th Congress
Status
Spectrum: Moderate Partisan Bill (Democrat 9-2)
Status: Introduced on February 24 2012 - 25% progression, died in committee
Action: 2012-02-24 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 24 2012 - 25% progression, died in committee
Action: 2012-02-24 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Prescription Drug Labeling Promotion Act of 2012 - Directs the Secretary of Health and Human Services (HHS) to establish a working group to develop best practices on access to prescription drug labeling for the visually impaired. Requires the working group to: (1) include equal representation of consumer and industry advocates; (2) promulgate guidance on best practices for pharmacies to ensure that blind and visually impaired individuals have safe, consistent, reliable, and independent access to the information in the labeling of prescription drugs; (3) consider the use of Braille, specified auditory means, and enhanced visual means to provide such access; and (4) consider whether there are technical, financial, manpower, or other factors that may fundamentally impact the ability of pharmacies with 20 or fewer retail locations to implement the best practices. Directs the Commissioner of Food and Drugs (FDA) to conduct an informational and educational program to inform the public and pharmacists about such guidance and practices. Directs the Comptroller General: (1) 18 months after such guidance and practices are published, to review pharmacy compliance and the extent to which access barriers continue; and (2) by September 30, 2016, to report on such review, including recommendations for reducing such barriers.
Title
Prescription Drug Labeling Promotion Act of 2012
Sponsors
Sen. Edward Markey [D-MA] | Rep. Suzanne Bonamici [D-OR] | Rep. Lacy Clay [D-MO] | Rep. Joe Courtney [D-CT] |
Rep. James McGovern [D-MA] | Rep. James Moran [D-VA] | Rep. David Price [D-NC] | Rep. David Roe [R-TN] |
Rep. Ileana Ros-Lehtinen [R-FL] | Rep. Adam Smith [D-WA] | Rep. Jackie Speier [D-CA] |
History
Date | Chamber | Action |
---|---|---|
2012-02-24 | House | Referred to the House Committee on Energy and Commerce. |
Same As/Similar To
SB2516 (Related) 2012-05-07 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 389.
SB3187 (Related) 2012-07-09 - Became Public Law No: 112-144.
SB3187 (Related) 2012-07-09 - Became Public Law No: 112-144.
Subjects
Advisory bodies
Consumer affairs
Disability and paralysis
Government information and archives
Government studies and investigations
Health
Health information and medical records
Prescription drugs
Consumer affairs
Disability and paralysis
Government information and archives
Government studies and investigations
Health
Health information and medical records
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/112th-congress/house-bill/4087/all-info |
Text | https://www.congress.gov/112/bills/hr4087/BILLS-112hr4087ih.pdf |